BOPA website FREE sections for 3 months + 15 months membership for existing members

Dear All,

The BOPA committee are pleased to state that the e-learning modules, the general forum and all resources on the BOPA website are now free for all healthcare professionals for a period of 3 months to help support us at a time we all need this the most.  The COVID19 page is already free to all.

To access these areas please join as a free member here: https://www.bopa.org.uk/join-bopa/

All existing paid members will be given an extension of 3 months to their subscription.  All new members who are joining as a paid member will be given a 15/14/13 months subscription (depending on what month they join).

Please share with your colleagues and we hope that this will help all pharmacy staff, whatever their role, during this period of time.

Stay Safe

Latest News

By BOPA Executive Committee on 4th November 2025

Joint BOPA and PASG Position Statement Safer Handling of Hazardous SACT Drugs: A Pharmacy Workforce Position Statement

BOPA and PASG Publish Joint Position Statement on the Safer Handling of Hazardous SACT Drugs The British Oncology Pharmacy Association (BOPA) and the NHS Pharmaceutical Aseptic Services Group (PASG) have…

Read article
By Jennifer Allen - LCC Lead on 4th November 2025

BOPA’s Let’s Communicate Cancer (LCC) series receives re-accreditation from the Royal Society for Public Health (RSPH)

The Let’s Communicate Cancer (LCC) series, available for free on the BOPA website CancerHUB: Home Page – BOPA, has recently received re-accreditation from the Royal Society for Public Health which…

Read article
By BOPA Executive Committee on 3rd November 2025

BOPA’s Submission for the National Cancer Plan for England 2025 – Call for Evidence

With the National Cancer Plan 2025 for England Publication imminent (Shaping the national cancer plan – GOV.UK) – please find BOPA’s Submission for the call for evidence below: BOPA Submission…

Read article
By BOPA IOSIG on 1st November 2025

IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events

  IOCN UK-wide Survey: Access to Immunosuppressants for ICI Adverse Events Have your say on a critical issue affecting immunotherapy patients across the UK. The IOCN and UKSACT Board have…

Read article